Latest from Johns Hopkins Cancer Center

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.
Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.
According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.
Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.
Cynthia L. Sears, MD, professor of Medicine, Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses bacteria possibly influencing the development of colon cancer.
Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.
?Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discusses the role of the PD-L1 biomarker and other biomarkers on the horizon for the use in immunotherapy.
Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.
Publication Bottom Border
Border Publication